Hormonal abnormalities leading to disorders of sexual development

References

• Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement on management of interesex disorders. Pediatrics1118, e488–e500 (2006).
   Google Scholar
• Jost A. A new look at the mechanisms controlling sex differentiation in mammals. Johns Hopkins Med. J.130, 38–53 (1972).
   PubMedGoogle Scholar
• Blecher SR, Erickson RP. Genetics of sexual development: a new paradigm. Am. J. Med. Genet.143A, 3054–3068 (2007).
   PubMed Web of Science ®Google Scholar
• Hanley NA, Arlt W. The human fetal adrenal cortex and the window of sexual differentiation. Trends Endocrinol. Metab.17(10), 391–397 (2006).
   Google Scholar
• Cotinot C, Pailhoux E, Jaubert F, Fellous M. Molecular genetics of sex determination. Semin. Reprod. Med.20(3), 157–167 (2002).
   Google Scholar
• Kim Y, Capel B. Balancing the bipotential gonad between alternative organ fates: a new perspective on an old problem. Dev. Dyn.235, 2292–2300 (2006).
   PubMedGoogle Scholar
• DiNapoli L, Capel B. SRY and the standoff in sexual determination. Mol. Endocrinol.22(1), 1–9 (2008).
   PubMedGoogle Scholar
• Parma P, Radi O, Vidal V et al. R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat. Genetics38(11), 1304–1309 (2006).
   PubMedGoogle Scholar
• Ostrer H. Sexual differentiation. Semin. Reprod. Med.18(1), 41–49 (2000).
   Google Scholar
• Miyamoto Y, Taniguchi H, Hamel F, Silversides DW, Viger RS. A GATA4/WT1 cooperation regulates transcription of genes required for mammalian sex determination and differentiation. BMC Mol. Biol.9(9), 44 (2008).
   PubMed Web of Science ®Google Scholar
• di Clemente N, Belville C. Anti-Müllerian hormone receptor defect. Best Pract. Res. Clin. Endocrinol. Metabol.20(4), 599–610 (2006).
   Google Scholar
• Salhi I, Cambon-Roques S, Lamarre I et al. The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem. J.379, 785–793 (2004).
   PubMedGoogle Scholar
• Hannema SE, Hughes IA. Regulation of wolffian duct development. Horm. Res.67(3), 142–151 (2007).
   Google Scholar
• Siiteri PK, Wilson JD. Testosterone formation and metabolism during male sexual differentiation in the human embryo. J. Clin. Endocrinol. Metabol.38, 113–125 (1974).
   PubMed Web of Science ®Google Scholar
• Goto M, Piper HK, Marcos J et al. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J. Clin. Invest.116, 953–960 (2006).
   PubMed Web of Science ®Google Scholar
• Krone N, Hanley NA, Arlt W. Age-specific changes in sex steroid biosynthesis and sex development. Best Pract. Res. Clin. Endocrinol. Metabol.21(3), 393–401 (2007).
   Google Scholar
• Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab.19, 432–438 (2004).
   Google Scholar
• Sobel V, Zhu YS, Imperato-McGinley J. Fetal hormones and sexual differentiation. Obstet. Gynecol. Clin. N. Am.31, 837–856 (2004).
   Google Scholar
• Bardoni B, Zanaria E, Guioli S et al. A dosage sensitive locus at Xp21is involved in male to female sex reversal. Nat Genet.7(4), 497–501 (1994).
   PubMedGoogle Scholar
• Wilhelm D, Palmer S, Koopman P. Sex determination and gonadal development in mammals. Physiol. Rev.87, 1–28 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen-Haguenauer O, Picard JY, Mattéi MG et al. Mapping of the gene for anti-müllerian hormone to the short arm of human chromosome 19. Cytogenet. Cell. Genet.44(1), 2–6 (1987).
   PubMedGoogle Scholar
• Knebelmann B, Boussin L, Guerrier D et al. Anti-Mullerian hormone Bruxelles: a nonsense mutation associated with the persistent mullerian duct syndrome. Proc. Natl Acad. Sci. USA88(9), 3767–3771 (1991).
   PubMed Web of Science ®Google Scholar
• Di Clemente N, Wilson C, Faure E et al. Cloning, expression, and alternative splicing of the receptor for anti-mullerian hormone. Mol. Endocrinol.8, 1006–1020 (1994).
   PubMedGoogle Scholar
• Imbeaud S, Belville C, Messika-Zeitoun L et al. A 27 base-pair deletion of the anti-mullerian type II receptor gene is the most common cause of the persistent mullerian duct syndrome. Hum. Mol. Genet.5, 1269–1277 (1996).
   PubMed Web of Science ®Google Scholar
• Laue L, Wu SM, Kudo M et al. A nonsense mutation of the human luteinizing hormone receptor gene in Leydig cell hypoplasia. Hum. Mol. Genet.8, 1429–1433 (1995).
   Google Scholar
• Laue L, Chan WY, Hsueh AJ et al. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc. Natl Acad. Sci. USA92(6), 1906–1910 (1995).
   PubMed Web of Science ®Google Scholar
• Berthezene F, Forest MG, Grimaud JA et al. Leydig cell agenesis: a cause of male pseudohermaphroditism. N. Engl. J. Med.295, 969–972 (1976).
   PubMed Web of Science ®Google Scholar
• Berube D, Luu-The V, La Chance Y et al. Assignment of the human 3α-hydroxysteroid dehydrogenase gene (HSDα3) to the p13 band of chromosome 1. Cytogenet. Cell Genet.52, 199–200 (1989).
   Google Scholar
• Rheaume E, La Chance Y, Zhao H-F et al. Structure and expression of a new complementary DNA encoding the almost exclusive 3α-hydroxysteroid dehydrogenase/5-4 isomerase gene in human adrenals and gonads. Mol. Endocrinol.5, 1147–1157 (1991).
   PubMedGoogle Scholar
• Simard J, Rheaume E, Mebarki F et al. Molecular basis of human 3αdehydrogenase deficiency. J. Steroid Biochem. Mol. Biol.53, 127–138 (1995).
   PubMedGoogle Scholar
• Rheaume E, Simard J, Morel Y et al. Congenital adrenal hyperplasia due to point mutations in the type II 3α-hydroxysteroid dehydrogenase gene. Nat. Genet.1, 239–245 (1992).
   PubMed Web of Science ®Google Scholar
• Miura K, Yasuda K, Yanase K et al. Mutation of cytochrome P-45017α gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. J. Clin. Endocrinol. Metab.81, 3797–3801 (1996).
   PubMed Web of Science ®Google Scholar
• Yanase T, Simpson ER, Waterman MR. 17α-hydroxylase deficiency: from clinical investigation to molecular definition. Endocr. Rev.12, 91–108 (1991).
   PubMed Web of Science ®Google Scholar
• Yanase T. 17α-hydroxylase/17,20-lyase defects. J. Steroid Biochem. Mol. Biol.53, 153–157 (1995).
   PubMed Web of Science ®Google Scholar
• Oshiro C, Takasu N, Wakugami T et al. Seventeen α-hydroxylase deficiency with one base pair deletion of the cytochrome P450c17 (CYP17) gene. J. Clin. Endocrinol. Metab.80, 2526–2529 (1995).
   PubMed Web of Science ®Google Scholar
• Geller DH, Auchus RJ, Mendonca BB et al. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat. Genet.17, 201–205 (1997).
   PubMed Web of Science ®Google Scholar
• Luu-The V. Analysis and characteristics of multiple types of human 17β hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol.76, 143–151 (2001).
   PubMed Web of Science ®Google Scholar
• Geissler WM, Davis DL, Wu I et al. Male pseudohermaphroditism caused by mutations of testicular 17α-hydroxysteroid dehydrogenase 3. Nat. Genet.7, 34–39 (1994).
   PubMed Web of Science ®Google Scholar
• Bangsboll S, Qvist I, Lebech PE, Lewinsky M. Testicular feminization syndrome and associated gonadal tumors in Denmark. Acta Obstet. Gynecol. Scand.71, 63–66 (1992).
   PubMed Web of Science ®Google Scholar
• Lubahn DR, Joseph DR, Sar M et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis, and gene expression in prostate. Mol. Endocrinol.2, 1265–1275 (1988).
   PubMed Web of Science ®Google Scholar
• Edwards A, Hammond HA, Jin L et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics12, 241–253 (1992).
   PubMed Web of Science ®Google Scholar
• La Spada AR, Wilson EM, Lubahn DB et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature352, 77–79 (1991).
   PubMed Web of Science ®Google Scholar
• Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum. Mol. Genet.4, 523–527 (1995).
   PubMed Web of Science ®Google Scholar
• Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res.22, 3181–3186 (1994).
   PubMed Web of Science ®Google Scholar
• Batch JA, Williams, DM, Davies HR et al. Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome. Hum. Mol. Genet.1, 497–503 (1992).
   Google Scholar
• Patterson MN, McPhaul MJ, Hughes IA. Androgen insensitivity syndrome. Baillieres Clin. Endocrinol. Metab.8, 379–404 (1994).
   Google Scholar
• MacLean HE, Warne GL, Zajac JD. Defects of androgen receptor function: from sex reversal to motor neurone disease. Mol. Cell. Endocrinol.112, 133–141 (1995).
   PubMed Web of Science ®Google Scholar
• McPhaul MJ, Marcelli M, Zoppi S et al. Mutations in the ligand-binding domain of the androgen receptor cluster in two regions of the gene. J. Clin. Invest.90, 2096–2101 (1992).
   Google Scholar
• Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Ann. Rev. Biochem.63, 25–61 (1994).
   PubMed Web of Science ®Google Scholar
• Boudon C, Lobaccaro JM, Lumbroso S et al. A new deletion of 5a-reductase type 2 gene in a Turkish family with 5α-reductase deficiency. Clin. Endocrinol.43, 183–188 (1995).
   Google Scholar
• Vilchis F, Valdez E, Ramos L, Garcia R, Gomez R, Chavez B. Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia. J. Hum. Genet.53, 401–406 (2008).
   Google Scholar
• New MI. Congenital adrenal hyperplasia. In: Endocrinology (3rd Edition) De Groot L (Ed.). WB Saunders, PA, USA 1813–1835 (1995).
   Google Scholar
• Thompson R, Seargent L, Winter JSD. Screening for congenital adrenal hyperplasia: distribution of 17α-hydroxyprogesterone concentrations in neonatal blood spot specimens. J. Pediatr.114, 400–404 (1989).
   PubMed Web of Science ®Google Scholar
• Godo B, Visser HKA, Degenhart JH. Plasma 17OH-progesterone in full-term and preterm infants at birth and during the early neonatal period. Horm. Res.15, 65–71 (1981).
   Google Scholar
• Miller WL. Genetics, diagnosis and management of 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab.78, 241–246 (1994).
   PubMed Web of Science ®Google Scholar
• New MI, White PC. Genetic disorders of steroid hormone synthesis and metabolism. Baillieres Clin. Endocrinol. Metab.9, 525–554 (1995).
   Google Scholar
• Speiser PW, Dupont J, Zhu D et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Invest.90, 584–595 (1992).
   PubMed Web of Science ®Google Scholar
• Kolon TF, Lamb DJ. Gene transcription and translation. Cont. Urol.10(11), 42–67 (1998).
   Google Scholar
• Tusie-Luna M-T, Traktmon P, White PC. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J. Biol. Chem.265, 20916–20922 (1990).
   PubMed Web of Science ®Google Scholar
• Pang S, Wallace MA, Hofman L et al. Worldwide experience in newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics81, 866–874 (1988).
   PubMed Web of Science ®Google Scholar
• Pollack M, Levine LS, Duchon M et al. Prenatal diagnosis of CAH due to 21-hydroxylase deficiency by HLA typing of cultured amniotic fluid cells. Pediatr. Res.13, 384A (1979).
   Google Scholar
• Nimkarn S, New MI. Prenatal diagnosis and treatment of congenital adrenal hyperplasia. Horm. Res.67, 53–60 (2006).
   Google Scholar
• Mornet E, Dupont J, Vitek et al. Characterization of two genes encoding human steroid 11 α-hydroxylase (P45011B). J. Biol. Chem.264, 20961–20967 (1989).
   PubMed Web of Science ®Google Scholar
• Chua SC, Szabo P, Vitek A et al. Cloning of cDNA encoding steroid 11α-hydroxylase (P450c11). Proc. Natl Acad. Sci. USA84, 7193–7197 (1987).
   PubMed Web of Science ®Google Scholar
• White PC, Speiser PW. Steroid 11α-hydroxylase deficiency and related disorders. Endocrinol. Metab. Clin. North Am.23, 325–339 (1994).
   Google Scholar
• Nakagawa Y, Yamada M, Ogawa H et al. Missense mutation in CYP11B1 (CGA [Arg384] α GGA [Gly]) causes steroid 11 α-hydroxylase deficiency. Eur. J. Endocrinol.132, 286–289 (1995).
   PubMedGoogle Scholar
• Rosler A, Lieberman A. Enzymatic defects of steroidogenesis: 11 α-hydroxylase deficiency congenital adrenal hyperplasia. In: Adrenal Diseases in Childhood: Pediatric Adolescent Endocrinology (Volume 13). New MI, Levine LS (Eds). Karger, Basel, Switzerland 47–71 (1984).
   Google Scholar
• Ulick S, Wang JZ, Morton DH. The biochemical phenotypesof two inborn errors in the biosynthesis of aldostereone. J. Clin. Endocrinol. Metab.74, 1415–1420 (1992).
   Google Scholar
• Pang S, Levine LS, Lorenzen F et al. Hormonal studies in obligate heterozygotes and siblings of siblings with 11α-hydroxylase deficiency congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab.50, 586–589 (1980).
   PubMedGoogle Scholar
• Schumert Z, Rosenmann A, Landau H et al. 11-deoxycortisol in amniotic fluid: prenatal diagnosis of congenital adrenal hyperplasia due to 11 α-hydroxylase deficiency. Clin. Endocrinol.12, 257–260 (1980).
   Google Scholar
• Rosler A, Lieberman E, Rosenmann A et al.: Prenatal diagnosis of 11α-hydroxylase deficiency congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab.49, 546–551 (1979).
   Google Scholar